This study indicates that N-(2-hydroxypropyl)methacrylamide homopolymers and copolymers containing oligopeptide sequences terminated in carboxylic acid groups, amine groups, aromatic units, or puromycin have no prominent effect on the porcine complement system in vitro. Inhibition of both pathways of the complement system occurred at concentrations highly exceeding the dose suitable for therapeutic purposes.
Get full access to this article
View all access options for this article.
References
1.
J. Kopecek, Biomaterials, 5, 19 (1984).
2.
R. Duncan and J. Kopecek, Adv. Polym. Sci., 57, 51 (1984).
3.
J. Kopecek, P. Rejmanová, R. Duncan, and J.B. Lloyd, Ann. N.Y. Acad. Sci., 446, 93 (1985).
4.
R. Duncan, J.B. Lloyd, P. Rejmanová, and J. Kopecek, Makromol. Chem. Suppl., 9, 3 (1985).
5.
P. Rejmanová , J. Kopecek, R. Duncan, and J.B. Lloyd, Biomaterials, 6, 45 (1985).
6.
R. Duncan, H.C. Cable, J.B. Lloyd, P. Rejmanová, and J. Kopecek, Makromol. Chem., 184, 1997 (1983).
7.
J. Kopecek and P. Rejmanová, in Controlled Drug Delivery, Vol. I, S. D. Bruck, ed., CRC Press, Boca Raton, FL, p. 81 (1983).
8.
L. Sprincl, J. Exner, O. Sterba, and J. Kopecek, J. Biomed. Mater. Res., 10, 953 (1976).
9.
S.A. Cartlidge , R. Duncan, J.B. Lloyd, P. Rejmanová, and J. Kopecek, J. Cont. Rel., 3, 55 (1986).
10.
R. Duncan, L.C.W. Seymour, L. Scarlett, J.B. Lloyd, P. Rejmanová, and J. Kopecek, Biochim. Biophys. Acta., in press.
11.
B. Rihová and J. Kopecek, J. Cont. Rel., 2, 289 (1985).
12.
B. Rihová, J. Kopecek, K. Ulbrich, J. Pospisil, and P. Mancal, Biomaterials, 5, 143 (1984).
13.
B. Rihová, K. Ulbrich, J. Kopecek, and P. Mancal, Folia Microbiol., 28, 217 (1983).
14.
S.S. Asghar , Pharmacol. Rev., 36, 223 (1984).
15.
J. Kopecek , P. Rejmanová, and V. Chytrý, Makromol. Chem., 182, 799 (1981 ).
16.
J. Strohalm and J. Kopecek, Angew. Makromol. Chem., 70, 109 (1978).
17.
P. Rejmanová , J. Labský, and J. Kopecek, Makromol. Chem., 178, 2159 (1977 ).
18.
J. Kopecek , Makromol. Chem., 178, 2169 (1977 ).
19.
P. Rejmanová , B. Obereigner, and J. Kopecek, Makromol. Chem. , 182, 1899 (1981).
20.
K. Ulbrich , B. Schmidt, and H. Ringsdorf, Makromol. Chem., to be published.
21.
R. Duncan, H.C. Cable, P. Rejmanová, J. Kopecek, and J.B. Lloyd, Biochim. Biophys. Acta., 799, 1 (1984).
22.
P.J. Lachmann , M.J. Hobart, and W.P. Aston, in Handbook of Experimental Immunology , 2nd Ed., D. M. Weir, ed., Blackwell, Oxford , U.K., p. 5.1 (1973).
23.
M.J. Rapp and T. Borsos, MolecularBasis of Complement Action, Appleton-Century-Crofts, New York, N.Y., p. 75 (1970).
24.
M.M. Mayer, in Experimental Immunochemistry, E. A. Kabat and M. M. Mayer, eds., Thomas, Springfield, IL, p. 133 (1961).
25.
D L.Coleman, D.E.Gregonis, and J. D. Andrade, J. Biomed. Mater. Res., 16, 381 (1982).
26.
C.D. Ebert and S.W. Kim, in Medical Application of Controlled Release, Vol. II, R. S. Langer and D. L. Wise, eds., CRC Press, Boca Raton, FL, p. 77 (1984).
27.
M. Jozefowicz and J. Jozefonvicz, Pure Appl. Chem., 56, 1335 (1984).
28.
M. Mauzac, N. Aubert, and J. Jozefonvicz, Biomaterials, 3, 221 (1982).
29.
A.M. Fischer , M. Mauzac, J. Tapon-Bretaudiere, and J. Jozefonvicz, Biomaterials , 6, 198 (1985).
